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Objective. Two major causes of disability, major depression and obesity, share overlapping psychosocial and pathophysiological
etiologies. Studies are now focused on biological mechanisms linking the two illnesses, and there is interest in the role that
adipokines may have in mediating the association between obesity and depression. We reviewed the literature to look at what
is currently known about this association, focusing on the adipokines leptin, adiponectin, and resistin. Methods. A MEDLINE
search, citing articles from 1966 onward, supplemented by a review of bibliographies, was conducted to identify relevant studies.
Results. This paper identiﬁed plausible pathways underlying a link between adipokines and depression. Only a few studies have yet
beenconductedspeciﬁcallyexaminingthesebiomarkersinpatientswithdepression,buttheresultsareintriguing.Conclusion.This
paper is one of the ﬁrst to examine the association between adipokines and depression. It provides an overview of the physiological
role of adipokines and summarizes the data suggesting that they may be dysregulated in major depression. This area of research
may become increasingly important as new treatment strategies are developed.
1.Introduction
Obesity elevates the risk of developing a number of diseases,
including atherosclerosis, diabetes, nonalcoholic fatty liver
disease, certain cancers, and immune-mediated disorders
such as asthma [1–3]. There is also converging evidence
that negative mood states and stress create susceptibility
to physical illnesses such as the common cold and car-
diovascular disease, resulting in premature mortality [4–
6]. Underlying mechanisms such as chronic inﬂammation
have been extensively investigated as candidate pathways that
subsequently link obesity and depression in an attempt to
explain how each confers vulnerability to the other and
subsequently elevate as the risk for physical illness [7]. Other
potential mediators of the obesity-depression association,
such as changes in adipokines, however, have not yet been
well explored.
Adipose tissue is no longer considered an inert tissue
devoted to energy storage, and is now recognized as an
endocrine organ capable of secreting a variety of biologically
active components [8]. These secretory products called
“adipokines” include leptin, resistin, and adiponectin. A
number of these biomarkers are now being explored as a
meansofexplainingthelinkbetweenobesityanddepression,
and as a consequence, representing possible novel targets
in the treatment of mental illness [9, 10]. The primary
object of this paper was to review the literature regarding
the association between adipokines and major depressive
disorder (MDD). This novel area of investigation may lead
to new discoveries that help us understand depression and
obesity, conditions that represent the largest psychological
and physical causes of disability worldwide, respectively.
2. Methods
MEDLINEandPubMedsearcheswereconductedofEnglish-
language articles published between 1950 and May 2010
using the following search terms: major depressive disorder,
depression, cross-referenced with adipocytokine, adipokine,2 Journal of Obesity
leptin, resistin, and adiponectin. In addition, reference
lists from the identiﬁed publications were then manually
reviewed. The search was conducted most recently on May
20, 2010.
3. Evidence for an Association between
Adiopokines andDepressionLeptin
3.1. An Overview of the Role of Leptin. Most of the evidence
to date linking adipokines and MDD is focused on leptin.
Leptinisproducedprimarilybydiﬀerentiatedadipocytesand
exerts its inﬂuence on the central nervous system (CNS),
suppressing food intake and stimulating energy expenditure
[11]. It was initially identiﬁed as an antiobesity hormone,
acting as a negative feedback adiposity signal to control
energy homeostasis by interacting with its receptors in
the hypothalamus [12]. Under conditions of regular eating
cycles, leptin levels exponentially reﬂect the proportion of
adipose tissue [13], and the most important variable that
determines leptin concentration is body fat mass [14]. As a
consequence of its role in satiety, leptin was initially thought
to have an application in obesity treatment, but conversely,
obese individuals often have increased leptin concentrations
[15]. The high leptin levels associated with obesity are
thought to be caused by leptin resistance, much as high
insulin levels in type 2 diabetic patients are a consequence of
resistance to insulin. Leptin resistance may occur at several
levels, including impaired transport of leptin across the
blood brain barrier, reduced function of the leptin receptor,
and defects in leptin signal transduction [16, 17].
3.2. The Role of Leptin in Depression. The role of leptin
in the pathophsiology of psychiatric disorders in general,
and in depression in particular, is being explored. Leptin
insuﬃciency and/or leptin resistance may contribute to
vulnerabilitytodepression[9].Ratsexposedtochronicstress
have decreased levels of leptin and a variety of depressive-
like behaviors have been reduced by leptin administration
[18, 19]. The data on the role of leptin in humans is more
equivocal, however, and studies have reported increased [20,
21], decreased [22, 23], or unchanged [24] levels in people
with depression.
3.3. Mechanisms of a Leptin-Depression Association. Along
with its more clearly understood roles in energy metabolism,
leptin also plays a role in the bidirectional communication
between the hypothalamic pituitary adrenal (HPA) axis and
the adipose system; however, the relationship between these
systems have not been deﬁned and most likely involve
unknown factors. Leptin expression is also stimulated by
glucocorticoids [25] but chronic or high intensity stress
oﬀsets this stimulatory eﬀect and causes a reduction in
leptin levels [26]. There is also a link between leptin and
inﬂammation. Leptin is involved in modulating the immune
response and increases the production of proinﬂammatory
cytokines such as tumor necrosis-factor-alpha (TNF-a) and
interleukin-6 (IL-6) [27]. Given that MDD is considered to
be a proinﬂammatory state [7] and that dysregulation of the
HPA axis represents the most common biological alteration
found in depression [28], while further work is required
to characterize the neural circuits and signal transduction
pathways that mediate leptin’s action, there may be a
potential role for this hormone both to explain some of the
metabolic abnormalities associated with depression and as a
trait marker of MDD itself.
4. Adiponectin
4.1. An Overview of the Role of Adiponectin. Adiponectin is
primarily an adipocyte secretory protein involved in glucose
and lipid homeostasis [29], but it is also expressed by skeletal
muscle cells, cardiac myocytes, and endothelial cells [30–
32]. A negative correlation between obesity and circulating
adiponectin has been well established, and serum levels
of adiponectin are markedly decreased in individuals with
visceralobesityandstatesofinsulinresistance,suchasnonal-
coholicfattyliverdisease,atherosclerosis,andtype2diabetes
mellitus [33]. Adiponectin also has been increasingly linked
to mood states and may be of particular interest to explain
how stress arousal may impact psychiatric disease risk.
4.2. The Role of Adiponectin in Depression. The ﬁrst epidemi-
ological studies documenting an association between low
levels of adiponectin and an increased risk of MDD were
published in 2006 [34, 35]. Since that time, adiponectin has
become the most abundant adipose-derived plasma protein
with antiinﬂammatory qualities observed to be associated
with MDD [35, 36]. Circulating adiponectin levels have also
been shown to correlate inversely with anxiety scores, a
condition highly comorbid with depression [37].
Adiponectin has been suggested as a mediating factor in
the association between obesity and psychopathology, and
the adiponectin hypothesis stipulates that the link between
the two conditions is directly related to hypoadiponectine-
mia [36]. The results of studies examining adiponectin in
clinical populations have been variable, however. While the
original work in this area reported a decrease in plasma
adiponectin concentrations in symptomatic patients with
MDD [35] and an increase in adiponectin in patients with
depression that was successfully treated [34], other studies
have been unable to ﬁnd changes in people with depression
[10, 38, 39]. This eﬀect may be mediated by antidepressants
in the short-term [40] and weight gain over time [41], but
recent work suggests that the presence of weight gain and
depression also appears to be additive. The two conditions
appeartohaveagreatereﬀectonadiponectinthateitherdoes
separately [42], indicating that an underlying vulnerability
may be conferred and then compounded by either of the two
conditions and their resultant hypoadiponectinemia.
4.3. Mechanisms of an Adiponectin-Depression Association.
Adiponectin regulates the expression of several pro- and
antiinﬂammatory cytokines and has been shown to both
reduce secretion and attenuate the biological eﬀects of
TNF-a [43–45] and to induce the production of antiin-
ﬂammatory cytokines such as interleukin-10 (IL-10) andJournal of Obesity 3
interleukin-1 receptor antagonist (IL-1RA) [46]. Expres-
sion of adiponectin is also regulated by proinﬂammatory
mediators such as IL-6, which have been shown suppress
adiponectin transcription and translation [47]. Weight loss
is a potent inducer of adiponectin synthesis [48] and the
decreased synthesis of adiponectin, apparent in individuals
who are obese, might lead to dysregulation of the controls
that inhibit the production of proinﬂammatory cytokines,
thereby leading to the production of increased levels of
proinﬂammatory mediators. The HPA axis also plays a
role in adiponectin regulation; adiponectin gene expression
is reversibly downregulated by dexamethasone [49], and
glucocorticoids have been shown to inhibit adiponectin
function [50].
Interpretation of the role of adiponectin in depression
is complicated by potential confounding variables such
as weight, other cardiovascular risk factors, medical co-
morbidities, and the role of pharmacotherapy, but its role
is worth exploring. The links between adiponectin, inﬂam-
mation, and HPA axis dysregulation highlight a biologically
plausible mechanism linking it to MDD.
5.Resistin
5.1. An Overview of the Role of Resistin. Resistin is produced
by adipocytes, macrophages, myocytes, and pancreatic cells
[51], but its physiological role in humans is still uncertain
[52]. Initial animal studies suggested that obesity induced by
a high-fat diet or mutation of the leptin gene or receptor is
associated with increased circulating resistin concentrations
[53, 54]. Other groups, however, have observed opposite
results [55], showing that resistin expression was downreg-
ulated in rodent models of diet-induced obesity [56–58]a n d
suppressed by free fatty acids [59]. The proinﬂammatory
properties of resistin do suggest that it has a role in inﬂam-
matory processes, however [60], and it is likely involved in
the chronic inﬂammatory reactions associated with obesity
[58, 61, 62].
5.2. The Role of Resistin in Depression. As the role of resistin
in inﬂammation and obesity has not been deﬁned, there is
limited information to ascertain whether it contributes to
the increased risk of physical illness in people with MDD.
Only 3 studies have examined this adipokine as it relates to
depression, and of these, the results are variable. One study
found both an association between free cortisol and resistin
inpatientswithdepression[10]andasubsequentdecr easein
resistin when patients were successfully treated that was not
seen in medication nonresponders, while a separate study in
Chinese patients found no link between the two [39]. A third
study recently found a positive correlation between resistin
levels and depression [42], but in this case the increase was
for atypical, but not typical depressive symptoms only. These
ﬁndings support previous biological data on diﬀerences
between atypical and melancholic features subtypes of MDD
[63] and are consistent with the negative results of the
investigation reporting no association between resistin and
typical depressive symptoms [39].
5.3. Mechanisms of a Resistin-Depression Association. While
much is left to learn about the role of resistin, what we do
know does support the possibility of an association between
resistin and depression. Resistin has been reported to inhibit
dopamine and noradrenaline release in the hypothalamus
[64] and, thus, through its contribution to decreased
intrasynaptic monoamine levels, it could also predispose to
depressivesymptomatology.Italsohaslinkstoinﬂammation
and the HPA axis, and further work is required to investigate
its role in MDD.
6. The Role of Cortisol as a Mediator between
Adipokines, Obesity,and Depression
Cortisol is proposed as a pathophysiological mediator in
excess weight gain and recent reports have suggested that
a state of primary intracellular cortisol excess may exist
in obesity. This pseudohypercortisolism could be a result
of increased activity of 11β-hydroxysteroid dehydrogenase-
1( 1 1 β-HSD-1), the enzyme that reduces cortisone to
cortisol and is capable of elevating intracellular cortisol
levels in adipose tissue cells [65]. Interest in a link between
cortisol and MDD was initially stimulated by work with
Cushing’s disease, an illness characterized by cortisol excess
secondary to either endogenous hyperactivation of the
HPA axis or treatment with corticosteroids. The typical
physical phenotype of central obesity that accompanies this
neuroendrocrine dysregulation is often accompanied by an
alteration in mood that interestingly can be successfully
treated by removal of the pituitary or adrenal tumors or by
corticosteroid production inhibitors, rather than by use of
classical antidepressants [66].
The association between MDD and cortisol may be
accounted for in part by exposure to stress; chronic
stress leads to cortisol elevation and both retrospective
and prospective studies suggest that major psychological
stressors both precede the ﬁrst episode of a mood disorder
[67] and are related to relapse [68]. As a consequence of
elevated stress, a cascade of events occurs in the HPA axis
beginning with increased release of corticotrophin releasing
hormone (CRH) and arginine vasopressin (AVP) from the
paraventricular nucleus (PVN) of the hypothalamus. CRH
and AVP subsequently stimulate the release of adreno-
corticotropic hormone (ACTH) from the pituitary, which
travels via the peripheral circulation to the adrenals and
enhances the secretion of cortisol. Cortisol functions as a
feedback regulator of the HPA axis, acting via glucocorticoid
receptors (GR) in the hypothalamus, pituitary, and other
brain regions. A signiﬁcant subset of depressed persons
show: (1) elevations in the 24-h excretion of cortisol in
the urine; (2) elevations in plasma cortisol and ACTH;
(3) elevations in cerebrospinal ﬂuid levels of CRH; (4)
failure of feedback inhibition of cortisol secretion by the
cortisol analog dexamethasone; and (5) a blunted ACTH
but normal cortisol secretion to exogenously administered
CRH(reviewedin[69]).Theresolution ofallpreviouslydys-
regulated HPA axis parameters including hypercortisolemia,
blunted ACTH response to CRH, hypesecretion of CRH,4 Journal of Obesity
and adrenal hypertrophy following successful antidepressant
treatmentprovidesindependentsupportfortheinvolvement
of the HPA axis in depression [69–71]. All of the adipokines
reviewed above regulate HPA function in some way, and all
therefore have potential to impact circulating cortisol levels.
7. Summary
The secretory function of adipocytes has established adipose
tissue as an endocrine organ. Obesity is not only accompa-
nied by inﬂammation [72], but is also associated with altered
levels of the adipokines, favoring an increase in leptin and
resistin, a decrease in adiponectin, and alterations in levels of
cortisol. The changes in these biomarkers are more diﬃcult
to quantify in patients with MDD but an emerging body of
evidence suggests that further investigation is warranted to
describe the links between obesity, depression, and adiokine
levels.
Current mechanisms to explain the interrelationships
between depression and adiposity using structured equation
modeling hypothesized that depression promotes weight
accumulation, causing an inﬂammatory response, which in
turn entails either an expanded adipose tissue release of
IL-6 or a leptin-induced upregulation of IL-6 release by
white blood cells [73]. This explanation, while biologically
plausible, does not include the role of cortisol and more
recent data on an expanding role of adipokines in linking
stress and weight gain to inﬂammation and disease.
W h i l ew o r ki nt h i sa r e an e e d st ob ed o n ei no r d e rt o
identify the cause and eﬀect of these diﬀerent contributors,
there does appear to be evidence that would support
exploring this area further.
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